National Institute of Radiological Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan.
Materials Sciences Research Center, Japan Atomic Energy Agency, 1-1-1 Kouto, Sayo, Hyogo 679-5148, Japan.
Anal Methods. 2022 Jun 23;14(24):2439-2445. doi: 10.1039/d2ay00565d.
Internal exposure to actinides such as uranium and plutonium has been reduced using chelating agents for decorporation because of their potential to induce both radiological and chemical toxicities. This study measures uranium chemical forms in serum in the presence and absence of chelating agents based on X-ray absorption spectroscopy (XAS). The chelating agents used were 1-hydroxyethane 1,1-bisphosphonate (EHBP), inositol hexaphosphate (IP6), deferoxamine B (DFO), and diethylenetriaminepentaacetate (DTPA). Percentages of uranium-chelating agents and uranium-bioligands (bioligands: inorganic and organic ligands coordinating with uranium) dissolving in the serum were successfully evaluated based on principal component analysis of XAS spectra. The main ligands forming complexes with uranium in the serum were estimated as follows: IP6 > EHBP > bioligands > DFO ≫ DTPA when the concentration ratio of the chelating agent to uranium was 10. Measurements of uranium chemical forms and their concentrations in the serum would be useful for the appropriate treatment using chelating agents for the decorporation of uranium.
由于铀和钚等锕系元素具有放射性和化学毒性,因此使用螯合剂进行去锕以减少内暴露。本研究基于 X 射线吸收光谱(XAS)测量了血清中螯合剂存在和不存在时铀的化学形态。使用的螯合剂为 1-羟基亚乙基 1,1-二膦酸(EHBP)、六偏磷酸肌醇(IP6)、去铁胺 B(DFO)和二乙烯三胺五乙酸(DTPA)。基于 XAS 光谱的主成分分析,成功评估了血清中铀-螯合剂和铀-生物配体(生物配体:与铀配位的无机和有机配体)的溶解百分比。当螯合剂与铀的浓度比为 10 时,估计与血清中的铀形成配合物的主要配体如下:IP6>EHBP>生物配体>DFO>DTPA。测量血清中铀的化学形态及其浓度对于使用螯合剂进行去锕治疗非常有用。